Preclinical studies of first-generation synthetic BET inhibitors, such as JQ1 (thienotriazolodiazepine), have shown anticancer activity in murine and xenograft models of NMC, acute myeloid leukemia (AML), multiple myeloma, and Burkitt's lymphoma.[3] Specifically in NMC, suppression of the BRD4–NUT fusion gene that is known to drive NMC growth has resulted in the growth arrest of NMC cells. The gene discussed is NUTM1; the disease is acute myeloid leukemia.